Ligand Pharmaceuticals Balance Sheet
NASDAQ: LGNDHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ligand Pharmaceuticals financial position
At the end of fiscal 2025, Ligand Pharmaceuticals reported total assets of $1.56 billion, up 65.7% from a year earlier against total liabilities of $543.4 million. Shareholders' equity stood at $1.02 billion, or 65.2% of assets. The company held $174.9 million in cash and equivalents against $446.2 million of debt, a net debt position of $271.3 million.
The current ratio (current assets divided by current liabilities) was 22.23, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.44.
Summary generated from market data by MetaCap's automated system. Methodology
Ligand Pharmaceuticals balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 174.93M | 72.31M | 22.95M | 45.01M | 19.52M | 47.62M | 71.54M | 117.16M | 20.62M | 18.75M |
| Short-Term Investments | 558.59M | 183.86M | 147.35M | 166.86M | 321.59M | 363.57M | 998.32M | 601.22M | 181.04M | 122.30M |
| Receivables | 59.60M | 38.38M | 32.92M | 30.42M | 85.45M | 56.85M | 30.39M | 55.85M | 25.60M | 14.70M |
| Inventory | 9.13M | 14.11M | 23.97M | 13.29M | 27.33M | 26.49M | 7.30M | 7.12M | 4.37M | 1.92M |
| Total Current Assets | 832.27M | 331.56M | 237.43M | 263.60M | 464.75M | 500.56M | 1.12B | 870.54M | 237.02M | 163.05M |
| Property, Plant & Equipment | 3.57M | 15.13M | 15.61M | 12.48M | 13.19M | 13.19M | 7.18M | 5.37M | 4.21M | 1.82M |
| Goodwill | 101.54M | 105.25M | 103.37M | 0 | 105.67M | 189.66M | 95.23M | 86.65M | 85.96M | 72.21M |
| Intangible Assets | 225.44M | 266.65M | 299.61M | 342.45M | 376.69M | 595.33M | 210.45M | 219.79M | 228.58M | 204.71M |
| Total Assets | 1.56B | 941.77M | 787.22M | 762.67M | 1.30B | 1.36B | 1.49B | 1.26B | 671.02M | 601.59M |
| Accounts Payable | 3.24M | 5.23M | 2.43M | 5.31M | 8.40M | 3.78M | 2.42M | 4.18M | 2.26M | 2.73M |
| Total Current Liabilities | 37.45M | 37.11M | 16.78M | 98.81M | 41.66M | 100.11M | 17.00M | 82.25M | 238.87M | 227.13M |
| Long-Term Debt | 446.19M | 0 | — | — | — | — | — | — | — | — |
| Total Liabilities | 543.42M | 111.33M | 86.30M | 165.18M | 476.43M | 652.76M | 727.68M | 699.89M | 252.37M | 230.73M |
| Shareholders' Equity | 1.02B | 830.44M | 700.91M | 597.49M | 821.16M | 709.52M | 767.23M | 560.91M | 399.79M | 341.29M |
| Retained Earnings | 608.09M | 498.98M | 503.02M | 450.86M | 449.09M | 391.95M | 400.11M | -229.20M | -400.92M | -431.13M |
| Total Debt | 446.19M | 0 | — | — | — | — | — | — | — | — |
| Net Cash (Debt) | 287.33M | 256.17M | 170.31M | 211.87M | 341.11M | 411.19M | 1.07B | 718.38M | 201.66M | 141.05M |
| Shares Outstanding | 19.77M | 19.11M | 17.56M | 16.95M | 16.77M | 16.08M | 16.82M | 20.77M | 21.15M | 20.91M |
This table shows 10 annual periods of Ligand Pharmaceuticals's balance sheet, from FY 2025 back to FY 2016, across 18 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow LGND's reporting calendar. What is a balance sheet?